Rural Phone and Broadband Connectivity

Debate between Eric Ollerenshaw and Guy Opperman

Tuesday 3rd February 2015 Commons Chamber

[Eric Ollerenshaw]

I stand corrected; it has all the features of a monopoly. Let me give an example. One of the villages supposedly in the BT area is Dolphinholme, which lies between two villages that B4RN was going to wire up, so its wiring went through the village. Villagers there had been waiting for BT, but it had not yet turned up, so they asked B4RN to connect them. B4RN then began connecting those people who requested it. BT has since moved into the village and, instead of just replacing copper with fibre, is wiring the node all the way through in a way that it has not done anywhere else in Lancashire, and all for a village of just over 200 people. Why is that? It looks as though that multi-million pound business is trying to squeeze out a voluntary, not-for-profit organisation that is proving extremely successful.

[Guy Opperman]

The thrust of what my hon. Friend is saying is that BT will do anything it can to drive out alternative providers in our local areas.

[Eric Ollerenshaw]

Absolutely. As we have heard hon. Members shout from across the Chamber, it is the behaviour of a monopoly.

Another characteristic of a monopoly is a lack of transparency. Let me give another example. Two weeks ago a resident of the village of Scorton, which was to be wired up by BT, approached me to say that he was having problems getting in touch with BT to find out what was going on. He runs a medium-sized engineering company from home with national contracts. I took the first step of any constituency MP and asked BT what was going on. I was told that there were technical difficulties. Eventually, I went to meet the resident in Scorton and found that he had been told that BT was now de-scoping the area because it was too difficult—I had been told one story, and he had been told another.

I am still waiting, three years down the line, for BT to hand me a map showing exactly what it is doing. Let me explain to hon. Members that these are villages up in the Pennines. Then there are places, such as Glasson Dock, which lies on flat land on the coast just beyond Lancaster, that BT is not wiring up, even though there are more residents there than in Dolphinholme, where it is delivering fibre, fibre, fibre. I know that the Public Accounts Committee has looked at the situation, but I would ask it to look again at the BT situation.

Pancreatic Cancer

Debate between Eric Ollerenshaw and Guy Opperman

Tuesday 4th March 2014 Commons Chamber

[Eric Ollerenshaw]

rose—

[Guy Opperman (Hexham) (Con)]

I congratulate my hon. Friend on securing the debate and endorse what he says entirely. Does he agree that perhaps we should also consider going commando this Friday to raise male cancer awareness and show our general support for all cancers that people are struggling with today?

[Eric Ollerenshaw]

I am grateful for those well-timed interventions from my colleagues across the frontier.

What I am trying to get on the record is the fact that those two more months are critical in this particular cancer. Our worry is that two more months might not look good enough when the judgment is made, but for pancreatic cancer it is a massive improvement.

I also want to put on the record two other emerging possibilities. A useful and emerging new technology is NanoKnife. It carries out a process called irreversible electroporation, which destroys parts of the tumour while avoiding damage to vital tissue nearby, such as blood vessels. The process shrinks the tumour to a more manageable size, which might then allow more permanent surgical solutions. NanoKnife is currently available only through the private sector at one hospital in London.

A company called Novartis, has a treatment for neuroendocrine pancreatic cancer that is currently funded via the CDF in England. Although it is welcome that patients can access treatment via that route, we continue to argue for a long-term solution. In that context, we are worried about Andrew Dillon’s statement that, under the new system of value assessments that NICE is due to introduce in the autumn, only six out of 20 treatments assessed by NICE in the past year would be approved. A 30% approval rate is clearly not the long-term solution expected from the original concept of value-based pricing. In 2013, I understand, not one new cancer drug was approved by NICE. That issue, perhaps, is for a wider debate, but I hope the Minister understands that those arguing on behalf of pancreatic cancer patients are extremely worried about ever getting the new drugs on to the system and available for wider use across, hopefully, the whole United Kingdom.

Minister, this debate has been an unashamed appeal for support—from the charities concerned, the all-party group, the survivors and all those who have been affected by pancreatic cancer through the loved ones they have lost. We do not want others to go through our tragic experiences.